Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
News and Events

Featured Stories

Hot information:
Top 10 Global CDMO Enterprises| Top 10 Global Clinical Research Organizations in 2021| The Meaning of IND, NDA and ANDA
Sep 29,2022
Complete Process DMPK Service Helps PROTAC Drug Development
Through the principle of PROTAC technology, medicilon, combined with R&D cases, uses the perfect in vitro ADME and in vivo PK testing platform to establish a screening and IND evaluation system on PROTAC drugs based on small molecule compound research, focusing on drug solubility, permeability, metabolic stability, metabolite identification and in vivo PK studies, etc., to help customers quickly advance the development of PROTAC drugs.
More
Complete Process DMPK Service Helps PROTAC Drug Development
Sep 15,2022
Top 10 Global CDMO Enterprises
Lonza ranks first, and China's WuXi department (WuXi AppTec + WuXi Biologics) has ranked the second position in the world. Among the top 10, two Asian companies and European companies occupy the majority.
More
Top 10 Global CDMO Enterprises
Sep 14,2022
Top 10 Global CDMO in 2022
In recent years, the global CDMO industry has maintained steady growth. In terms of revenue, Switzerland's Lonza ranks first, with sales of 5.4 billion Swiss francs in 2021, a year-on-year increase of 20%.
More
Top 10 Global CDMO in 2022
Sep 14,2022
Domestic and Foreign Pharmaceutical CDMO Industry
The MAH system has brought unprecedented opportunities and challenges to the Chinese pharmaceutical industry. Combined with the current development of the world's biopharmaceutical industry, the article will take you to understand the development pattern and current situation of the pharmaceutical CDMO industry, and understand the background of the CDMO industry development driven by policies and dividends.
More
Domestic and Foreign Pharmaceutical CDMO Industry
Sep 13,2022
Innovative drug development ideas for topical skin preparations
Equipped with corresponding transdermal and testing instruments (Such as LC-MS/MS), medicilon can provide professional and efficient services in projects involving in vitro evaluation such as compound screening, new drug submission, pharmacological changes of marketed chemical drugs, consistency evaluation, and generic drug submission.
More
Innovative drug development ideas for topical skin preparations
Sep 13,2022
CDMO is Coming a Good Choice
CDMO, Contract development and manufacturing organization, mainly provides process development and preparation, process optimization, registration and validation batch production and commercialized and customized R&D and production services for pharmaceutical manufacturers and biotechnology companies, especially innovative products organizations.
More
CDMO is Coming a Good Choice
Sep 09,2022
Domestic and Global Market of ADC Drugs
ADC drugs​ are mainly used in the field of anti-tumor, which is one of the hot research directions in recent years. ADC is composed of three parts: monoclonal antibody (mAb), coupling chain (linker) and cytotoxic small molecule (cytotoxin/payload). tumor lesions.
More
Domestic and Global Market of ADC Drugs
Sep 09,2022
ADC Drug Research Report
The design idea of ADC drugs is to couple antibodies with cytotoxic drugs, so as to simultaneously exert the high specificity of antibodies and the high toxicity of cytotoxic small molecules.
More
ADC Drug Research Report
Sep 08,2022
Birth, Development and Prospect of ADC Drugs
ADC (antibody-conjugated drug) is not a new concept. As the early 20th century, the Nobel Prize winner in medicine, German scientist Paul Ehrlich, had proposed the concept of ADC and called ADC drugs " Magic Bullet". But it wasn't until the 1950s that research on ADC drugs took off.
More
Birth, Development and Prospect of ADC Drugs
Sep 07,2022
HER2 ADC Terminator?
If there were pharmaceutical companies involved in making PD-1 antibodies before 2012, they might have become companies with a valuation of tens of billions by now.
More
HER2 ADC Terminator?